Cooley advised Zoetis on its $1.35 billion aggregate principal amount of investment-grade unsecured senior notes, $600 million of 5.400% senior notes due 2025, and $750 million of 5.600% senior notes due 2032. Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. Eric Blanchard and Madison Jones led the Cooley team.